Public Meeting of the Presidential Commission for the Study of Bioethical Issues, 26012-26013 [2012-10513]
Download as PDF
<![CDATA[
26012
Federal Register / Vol. 77, No. 85 / Wednesday, May 2, 2012 / Notices
nature of those products, and the
currently limited selection of providers
to customers of those products.
Paragraphs III.C. and III.D. of the
Order provide certain protections to
Respondents’ current and future
customers so that they are free to avail
themselves of their rights and
opportunities post-acquisition.
Paragraph III.C. prohibits Respondents
from intentionally disrupting or limiting
service to customers except in specific,
enumerated circumstances. This
provision ensures that Respondents’
customers are protected in their ability
to conduct their day-to-day business by
designating inappropriate suspension of
service as a retaliatory act punishable
under Paragraph III.H. of the Order. In
order to address the possible chilling
effects of the industry’s historically
litigious reputation, Paragraph III.D.
grants Respondents’ current and future
customers the right to resolve any
disputes with Respondents through
arbitration.
mstockstill on DSK4VPTVN1PROD with NOTICES
C. Compliance and Notification
Requirements
Paragraph V. of the Order requires
Respondents to provide notice to the
Federal Trade Commission thirty (30)
days prior to any planned acquisition of
any firm that gathers, markets, or sells
CRE listings or CRE information in the
United States for a period of five (5)
years. For an additional five years
thereafter, the Order requires
Respondents to provide prior notice of
planned acquisitions of any such firms
with revenues of $15 million or greater.
Paragraph VI. of the Order appoints
Guy Dorey as Monitor to assure
Respondents’ ongoing compliance with
their obligations and responsibilities
under the Order. Among other
responsibilities, Paragraph VI.
empowers the Monitor, at Respondents’
expense, to review and audit
compliance with Order provisions
relating to the divestitures of assets and
information and to customers’ rights to
support Xceligent.
To assure that Respondents fully
comply with the obligations of
Paragraph II. of the Order, Paragraph
VII. of the Order allows the Commission
to appoint a Divestiture Trustee to
assign, grant, license, divest, transfer,
deliver, or otherwise convey the
relevant assets and information.
Paragraph VIII. of the Order requires
Respondents to submit periodic reports
of compliance. The Order requires
reporting every sixty (60) days for two
(2) years following the Order date, and
annually thereafter until the Order
terminates in ten (10) years.
VerDate Mar<15>2010
16:55 May 01, 2012
Jkt 226001
Paragraph IX. of the Order requires
Respondents to give the Commission
prior notice of certain events that might
affect compliance obligations arising
from the Order.
D. Additional Provisions
Paragraph X. of the Order provides
that the Order shall terminate after ten
(10) years.
The purpose of this analysis is to aid
public comment on the proposed order.
It is not intended to constitute an
official interpretation of the complaint
or proposed order, or to modify in any
way the proposed order’s terms.
By direction of the Commission,
Commissioner Ohlhausen not participating.
Donald S. Clark,
Secretary.
[FR Doc. 2012–10550 Filed 5–1–12; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Public Meeting of the Presidential
Commission for the Study of
Bioethical Issues
Presidential Commission for
the Study of Bioethical Issues, Office of
the Assistant Secretary for Health,
Office of the Secretary, Department of
Health and Human Services.
ACTION: Notice of meeting.
AGENCY:
The Presidential Commission
for the Study of Bioethical Issues will
conduct its ninth meeting in May. At
this meeting, the Commission will
discuss topics related to the ethical
issues associated with the development
of medical countermeasures for children
as well as access to, and privacy of,
human genome sequence data.
DATES: The meeting will take place on
Thursday, May 17, 2012, from 9 a.m. to
approximately 5:30 p.m.
ADDRESSES: The Embassy Row Hotel,
2015 Massachusetts Ave. NW.,
Washington, DC 20036. Telephone:
(202) 265–1600.
FOR FURTHER INFORMATION CONTACT:
Hillary Wicai Viers, Communications
Director, Presidential Commission for
the Study of Bioethical Issues, 1425
New York Ave. NW., Suite C–100,
Washington, DC 20005. Telephone:
(202) 233–3960. Email:
Hillary.Viers@bioethics.gov. Additional
information may be obtained at
www.bioethics.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to the Federal Advisory Committee Act
of 1972, Public Law 92–463, 5 U.S.C.
app. 2, notice is hereby given of the
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
ninth meeting of the Presidential
Commission for the Study of Bioethical
Issues (the Commission). The meeting
will be open to the public with
attendance limited to available space.
The meeting will also be webcast at
https://www.bioethics.gov.
Under authority of Executive Order
13521, dated November 24, 2009, the
President established the Commission.
The Commission is an advisory panel of
the nation’s leaders in medicine,
science, ethics, religion, law, and
engineering. The Commission advises
the President on bioethical issues
arising from advances in biomedicine
and related areas of science and
technology. The Commission seeks to
identify and promote policies and
practices that ensure scientific research,
health care delivery, and technological
innovation are conducted in a socially
and ethically responsible manner.
The main agenda items for the
Commission’s ninth meeting are, first, to
discuss the ethical issues associated
with the development of medical
countermeasures for children, and
second, to discuss issues of privacy of,
and access to, human genome sequence
data.
The draft meeting agenda and other
information about the Commission,
including information about access to
the webcast, will be available at
https://www.bioethics.gov.
The Commission welcomes input
from anyone wishing to provide public
comment on any issue before it.
Respectful debate of opposing views
and active participation by citizens in
public exchange of ideas enhances
overall public understanding of the
issues at hand and conclusions reached
by the Commission. The Commission is
particularly interested in receiving
comments and questions during the
meeting that are responsive to specific
sessions. Written comments will be
accepted at the registration desk and
comment forms will be provided to
members of the public in order to write
down questions and comments for the
Commission as they arise. To
accommodate as many individuals as
possible, the time for each question or
comment may be limited. If the number
of individuals wishing to pose a
question or make a comment is greater
than can reasonably be accommodated
during the scheduled meeting, the
Commission may make a random
selection.
Anyone planning to attend the
meeting who needs special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify Esther Yoo by telephone
at (202) 233–3960, or email at
E:\FR\FM\02MYN1.SGM
02MYN1
Federal Register / Vol. 77, No. 85 / Wednesday, May 2, 2012 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
Esther.Yoo@bioethics.gov in advance of
the meeting. The Commission will make
every effort to accommodate persons
who need special assistance.
Written comments will also be
accepted in advance of the meeting and
are especially welcome. Please address
written comments by email to
info@bioethics.gov, or by mail to the
following address: Public Commentary,
Presidential Commission for the Study
of Bioethical Issues, 1425 New York
Ave. NW., Suite C–100, Washington, DC
20005. Comments will be publicly
available, including any personally
identifiable or confidential business
information that they contain. Trade
secrets should not be submitted.
FOR FURTHER INFORMATION CONTACT:
Andrew D. Forsyth Ph.D. or Vera
Yakovchenko, MPH, Office of HIV/AIDS
and Infectious Disease Policy (OHAIDP),
(202) 205–6606.
SUPPLEMENTARY INFORMATION:
In July 2010, the White House
released the National HIV/AIDS Strategy
(NHAS) for the United States that
outlined four key goals: (1) Reduce the
number of people who become infected
with HIV; (2) increase access to care and
optimize health outcomes for people
living with HIV; (3) reduce HIV-related
health disparities; and (4) achieve a
more coordinated national response to
the HIV epidemic in the United States.1
Central to the latter goal were two
related directives. The first was to
Dated: April 23, 2012.
develop improved mechanisms to
Lisa M. Lee,
monitor, evaluate, and report on
Executive Director, Presidential Commission
progress toward achieving national
for the Study of Bioethical Issues.
goals. And the second was to simplify
[FR Doc. 2012–10513 Filed 5–1–12; 8:45 am]
grant administration activities by
BILLING CODE 4154–06–P
standardizing data collection and
reducing undue grantee reporting
requirements for federal HIV programs.
DEPARTMENT OF HEALTH AND
In December 2009, the White House
HUMAN SERVICES
also released its Open Government
Directive,2 which seeks to improve
Request for Information on Guidance
access to government data in a manner
for the Specification of a Secure,
that enhances transparency, fosters
Online Reporting System for
participation through the public’s
Streamlining Programmatic, Fiscal,
contribution of ideas and expertise to
and Other Data From DHHS-Funded
decision-making, and enhances
HIV Prevention, Treatment, and Care
collaboration through new partnerships
Services Grantees
within the federal government and
AGENCY: Office of the Assistant
between public and private institutions.
Secretary for Health, Office of the
Notwithstanding existing clearance
Secretary, Department of Health and
requirements or legitimate reasons to
Human Services.
protect information, the Directive
ACTION: Notice.
highlighted the need for the following:
(1) Timely and accessible online
SUMMARY: The Department of Health and
publication of government information;
Human Services (DHHS) is seeking to
(2) improved quality of government
identify interest and obtain information
information; (3) creation of a culture of
relevant to the design, deployment,
open government; and (4) establishment
operations, maintenance, and future
of a policy framework for Open
enhancement of a centralized, secure,
Government. The release of the
flexible data reporting system to
Directive was followed shortly
streamline the collection, processing,
thereafter by the DHHS Open
and sharing of programmatic, funding,
Government Plan,3 which seeks to build
and other data reported to DHHS
upon the White House’s emphasis on
Operating Divisions (OpDivs) by
transparency, collaboration, and
grantees funded to provide HIV
collaboration to ensure that the
prevention, treatment, and care services.
government works better for all
DATES: To be assured consideration,
Americans.
comments must be received at one of
An important contribution of the
the addresses provided below, no later
DHHS Open Government Plan is its
than 5 p.m. EST on May 17, 2012.
reference to new technological
ADDRESSES: Electronic responses are
developments that make it possible to
strongly preferred and may be addressed streamline the collection, sharing, and
to [HIVOpenData@hhs.gov]. Written
1 https://www.whitehouse.gov/administration/eop/
responses should be addressed to: U.S.
onap/nhas.
Department of Health and Human
2 https://www.whitehouse.gov/open/documents/
Services, Room 443–H, 200
open-government-directive.
Independence Ave. SW., Washington,
3 https://www.hhs.gov/open/plan/
DC 20201. Attention: HIV Open Data
opengovernmentplan/transparency/
dashboard.html.
Project.
VerDate Mar<15>2010
16:55 May 01, 2012
Jkt 226001
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
26013
processing of programmatic and fiscal
data in a manner that facilitates greater
transparency, participation, and
collaboration, even in such critical and
sensitive areas as the DHHS investment
in HIV prevention, treatment, and care
services. At present, DHHS OpDivs that
fund these services use a mixture of
non-interoperable information
processing systems to collect
programmatic, fiscal, and other data
from grantees. Moreover, these systems
often utilize different indicators to
monitor the progress of HIV/AIDS
programs that vary in their
specifications (e.g., numerators,
denominators, time frames) and other
key parameters. As a result, many
required HIV/AIDS data elements are
inconsistent, impede evaluation and
monitoring of all relevant DHHS-funded
services, and add undue burden to HIV
services grantees charged with reporting
obligations often from multiple DHHS
OpDivs.
Under consideration at DHHS is the
design, deployment, operations,
maintenance, and future enhancement
of a centralized, secure, flexible data
reporting information system to compile
programmatic, funding, and other data
reported to DHHS OpDivs by grantees
funded to provide HIV prevention,
treatment, and care services. In effect,
DHHS is exploring the possibility of
establishing a single data reporting tool
for funders, grantees, and sub-grantees
that builds upon or shares many of the
features of the Health Resources and
Services Administration’s (HRSA) Ryan
White HIV/AIDS Services Report (RSR),
which is a secure, online, data
collection system for programmatic and
fiscal data. Similarly, such a system
might share features central to the
National Institutes of Health’s Electronic
Research Administration (ERA), which
offers a one-stop solution ‘‘to manage
the receipt, processing, review, award
and monitoring of over $30 billion in
research and non-research grants’’ (see
https://era.nih.gov). Moreover, such a
system would offer a secure data
solution that permits internal and
external access to data, eliminates
paper-based reporting, and streamlines
the process of data collection and
sharing in a manner that advances the
DHHS Open Government Plan.
The HIV Open Data Project
envisioned might offer several benefits,
such as: (1) Improve mechanisms to
monitor, evaluate, and report on
progress toward achieving NHAS goals;
(2) ensure more coordinated program
administration; (3) utilize a common
protocol for establishing patient
identifiers to protect confidentiality and
de-identify client data; (4) reduce
E:\FR\FM\02MYN1.SGM
02MYN1
]]>Agencies
[Federal Register Volume 77, Number 85 (Wednesday, May 2, 2012)]
[Notices]
[Pages 26012-26013]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-10513]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Meeting of the Presidential Commission for the Study of
Bioethical Issues
AGENCY: Presidential Commission for the Study of Bioethical Issues,
Office of the Assistant Secretary for Health, Office of the Secretary,
Department of Health and Human Services.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The Presidential Commission for the Study of Bioethical Issues
will conduct its ninth meeting in May. At this meeting, the Commission
will discuss topics related to the ethical issues associated with the
development of medical countermeasures for children as well as access
to, and privacy of, human genome sequence data.
DATES: The meeting will take place on Thursday, May 17, 2012, from 9
a.m. to approximately 5:30 p.m.
ADDRESSES: The Embassy Row Hotel, 2015 Massachusetts Ave. NW.,
Washington, DC 20036. Telephone: (202) 265-1600.
FOR FURTHER INFORMATION CONTACT: Hillary Wicai Viers, Communications
Director, Presidential Commission for the Study of Bioethical Issues,
1425 New York Ave. NW., Suite C-100, Washington, DC 20005. Telephone:
(202) 233-3960. Email: Hillary.Viers@bioethics.gov. Additional
information may be obtained at www.bioethics.gov.
SUPPLEMENTARY INFORMATION: Pursuant to the Federal Advisory Committee
Act of 1972, Public Law 92-463, 5 U.S.C. app. 2, notice is hereby given
of the ninth meeting of the Presidential Commission for the Study of
Bioethical Issues (the Commission). The meeting will be open to the
public with attendance limited to available space. The meeting will
also be webcast at https://www.bioethics.gov.
Under authority of Executive Order 13521, dated November 24, 2009,
the President established the Commission. The Commission is an advisory
panel of the nation's leaders in medicine, science, ethics, religion,
law, and engineering. The Commission advises the President on
bioethical issues arising from advances in biomedicine and related
areas of science and technology. The Commission seeks to identify and
promote policies and practices that ensure scientific research, health
care delivery, and technological innovation are conducted in a socially
and ethically responsible manner.
The main agenda items for the Commission's ninth meeting are,
first, to discuss the ethical issues associated with the development of
medical countermeasures for children, and second, to discuss issues of
privacy of, and access to, human genome sequence data.
The draft meeting agenda and other information about the
Commission, including information about access to the webcast, will be
available at https://www.bioethics.gov.
The Commission welcomes input from anyone wishing to provide public
comment on any issue before it. Respectful debate of opposing views and
active participation by citizens in public exchange of ideas enhances
overall public understanding of the issues at hand and conclusions
reached by the Commission. The Commission is particularly interested in
receiving comments and questions during the meeting that are responsive
to specific sessions. Written comments will be accepted at the
registration desk and comment forms will be provided to members of the
public in order to write down questions and comments for the Commission
as they arise. To accommodate as many individuals as possible, the time
for each question or comment may be limited. If the number of
individuals wishing to pose a question or make a comment is greater
than can reasonably be accommodated during the scheduled meeting, the
Commission may make a random selection.
Anyone planning to attend the meeting who needs special assistance,
such as sign language interpretation or other reasonable
accommodations, should notify Esther Yoo by telephone at (202) 233-
3960, or email at
[[Page 26013]]
Esther.Yoo@bioethics.gov in advance of the meeting. The Commission will
make every effort to accommodate persons who need special assistance.
Written comments will also be accepted in advance of the meeting
and are especially welcome. Please address written comments by email to
info@bioethics.gov, or by mail to the following address: Public
Commentary, Presidential Commission for the Study of Bioethical Issues,
1425 New York Ave. NW., Suite C-100, Washington, DC 20005. Comments
will be publicly available, including any personally identifiable or
confidential business information that they contain. Trade secrets
should not be submitted.
Dated: April 23, 2012.
Lisa M. Lee,
Executive Director, Presidential Commission for the Study of Bioethical
Issues.
[FR Doc. 2012-10513 Filed 5-1-12; 8:45 am]
BILLING CODE 4154-06-P
